|
Founder and CEO
John Alam is an industry leader in translational medicine and has a track record of creating value to help build companies through clinical development success. Until May 2014, he was therapeutic area head for diseases of aging within Sanofi R&D. In that role he led all discovery and development activities at Sanofi directed at Alzheimer’s disease, as well as a number of other age-related diseases (Sarcopenia/Frailty, Osteoarthritis, Chronic Pain, others). Previously, from 1997 until 2008 he held positions of increasingly responsibility at Vertex Pharmaceuticals, Inc., including Chief Medical Officer and Executive Vice President Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. And, from 1991 to 1997, at Biogen, Inc, he led the clinical development of Avonex (interferon beta-1a) for multiple sclerosis. John currently is also a member of the board of directors of Alliance for Aging Research (AAR), a Washington DC based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Among other activities AAR convenes ACT-AD ("Accelerate Cures/Treatments for Alzheimers Disease"), a public-private partnership focused on accelerating the development of treatments that slow, halt or reverse the progression of Alzheimers disease. John received a S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Subsequently, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute. |
|
Co-Founder, Executive Chair
Sylvie Grégoire is former president of Human Genetic Therapies at Shire Pharmaceuticals, 2007 to 2013. Prior to that, from 2006 to 2007 she was executive chairman of IDM Pharma Inc., and from 2003 to 2004 president and chief executive officer in GlycoFi Inc. From 1995 until 2003 Sylvie held various leadership positions in Biogen, Inc, most recently as executive vice president of Technical Operations. Prior to Biogen, she was at Merck and Co, in clinical research and regulatory affairs for a period of 8 years. Sylvie currently serves as Chair of the Board at Corvidia, Inc; and is a member of the Board of Directors at Novo Nordisk A/S , ViFor Pharma and Perkin Elmer Corporation. Sylvie has a Pharmacy Doctorate degree from the State University of NY at Buffalo, a B.A. in Pharmacy from Laval University, Canada, and a Science College degree from Seminaire de Sherbrooke, Canada. |
|
VP, Finance and Administration
Kevin brings significant finance, accounting, operations and SEC reporting experience to EIP Pharma, having served more than 18 years in the life science industry in both early-stage and publicly traded companies. From 2014 to 2017, he was Vice President of Finance and Chief Accounting Officer at Enumeral. Before Enumeral, he worked with various biotechnology and medical device companies in Vice President of Finance & Administration and Controller roles, including having been the Corporate Controller and Principal Accounting Officer of Nitromed, Inc., a publicly traded, cardiovascular-focused pharmaceutical company. At Nitromed, Kevin was responsible for SEC reporting, financial planning, risk management, treasury, the initiation of the company's Sarbanes-Oxley compliance efforts, and financial and accounting support. Before entering the life sciences industry, he held the position of audit supervisor within the technology assurance group of PricewaterhouseCoopers LLP. Kevin earned a B.S. in business management from the University of Hartford, an M.B.A. from Boston University and an M.A. in accounting from Suffolk University. He is a certified public accountant in the Commonwealth of Massachusetts. |
|
VP, Clinical Development
Kelly Blackburn has more than 25 years experience in clinical development operations, most recently as VP, Clinical Affairs at aTyr Pharma and as VP, Clinical Development Operations at Vertex Pharmaceuticals. Notably she had the senior global clinical operational responsibility for three major novel therapeutics: Kalydeco® for the treatment of cystic fibrosis, Incivek® for hepatitis C, and Velcade® for multiple myeloma. Kelly has a B.S. degree in biochemistry from the University of New Hampshire and a Master of Health Administration degree from Quinnipiac University. She is an active board member of the Hildebrand Family Self-Help Center, Cambridge MA; and long-standing long standing volunteer case reviewer and emergency foster care mother for the Department of Children and Families in Massachusetts. |
|
VP, Non-Clinical Development
Darryl Patrick is responsible for regulatory affairs and non-clinical development. Darryl has been in pharmaceutical R&D for 30 years. At Merck Research Laboratories he was responsible for numerous preclinical development programs and eventually became Vice President, Worldwide Safety Assessment responsible for preclinical safety evaluation of all development programs and a member of Merck Research Laboratories management committees. From 2004 to 2011 he was at Vertex Pharmaceuticals as Vice President, Exploratory Development, ultimately responsible for Toxicology, Drug Metabolism and Clinical Pharmacology. For his excellence and success in preclinical R&D Darryl has received numerous awards, including as a member of the team that won the prestigious Prix Galien in 2000 for their work on Singular®. He started his career in veterinary sciences with the US Air Force becoming Chief of Diagnostic and Comparative Medicine for the Uniformed Services, University of Health Sciences. He is trained in veterinary anatomy, laboratory animal pathology and veterinary internal medicine; with a DVM from Michigan State University and a PhD from Iowa State University. |
